Cystic fibrosis campaigners say they're shocked at the HSE's decision not to fund the use of drug Orkambi to treat the condition.
According to the Sunday Business Post the authority has decided the cost of the drug – understood to be over 150,000 euro a year – is too expensive and that it doesn't deliver enough benefits to patients.
Negotiations on its use had been ongoing for almost six months with an official confirmation of its rejection expected tomorrow morning.
